Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
SGMT vs CAMP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SGMT Captures Overall Composite Edge (52.6 HOLD vs 43.9 HOLD), While CAMP Leads 3–2 on Growth & Valuation Pillars
SGMT Overall Winner
6-Pillar Tally: SGMT 2 – 3 CAMP (1 Tie)
Matrix Metrics: SGMT 6 – 1 CAMP
As of Nov 17, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (52.6/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. SGMT trades at $9.78 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin).
- Growth vs. Quality Trade-Off: SGMT earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. CAMP 43.9/100 HOLD) and 2.08β · 84% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: SGMT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.5); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SGMT vs CAMP
SGMT
Head-to-Head Winner
Sagimet Biosciences Inc. Series A Common Stock
$9.78
-3.5% 1D
Market Cap
$735.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
2.08β · 84% Vol
Unified Composite Score
52.6
HOLD
Tech 36.0
Fund 54.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
CAMP
CAMP4 Therapeutics Corporation Common Stock
$4.00
+3.63% 1D
Market Cap
$238.5M
TTM Revenue
$5.3M
Forward P/E
N/M
Beta / 30D Vol
1.35β · 94% Vol
Unified Composite Score
43.9
HOLD
Tech 34.0
Fund 40.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (SGMT 2 – 3 CAMP)
1. Valuation Multiples
CAMP
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
26.6x
2. Growth & Scale
CAMP
Revenue Growth (YoY)
+0.0%
+138.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$5.3M
Market Cap
$735.2M
$238.5M
3. Profitability & Quality
SGMT
Gross Margin
N/A
N/A
Operating Margin
0.0%
-991.8%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-29.5%
-146.1%
4. Balance Sheet & Cash Flow
CAMP
Cash Generation (TTM)
-$44M
-$26M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$109M Net Cash
$97M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SGMT
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
81.6% (5th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Distribution
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SGMT (6) vs CAMP (1)| Institutional Metric | SGMT | CAMP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $735.2M | $238.5M | SGMT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +138.9% | CAMP | |
| Operating Margin (TTM) | 0.0% | -991.8% | SGMT | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -29.5% | -146.1% | SGMT | |
| 52-Week Range Position | 76% ($4–$11) | 23% ($3–$8) | SGMT | |
| Beta / 30D Volatility | 2.08β · 84% Vol | 1.35β · 94% Vol | SGMT | |
| Unified Institutional Score | 52.6 / 100 (HOLD) | 43.9 / 100 (HOLD) | SGMT | |
| Trailing 12M Revenue (USD) | N/A | $5.3M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 26.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$44M ($109M Net Cash) | -$26M ($97M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CAMP +17.06 pp
3M Horizon
SGMT +6.37 pp
6M Horizon
SGMT +53.07 pp
1Y Horizon
SGMT +28.57 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SGMT Revenue | CAMP Revenue | SGMT Op. Margin | CAMP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2023 | $0M | $0M | -1537.0% | -14822.6% | SGMT |
| FY2024 | N/A | $0M | N/A | -8142.3% | CAMP |
| FY2025 | N/A | $0M | N/A | -1502.4% | CAMP |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SGMT
BREAKOUT
Current IV
81.6%
IV Percentile
5th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SGMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CAMP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SGMT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CAMP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SGMT vs CAMP Key Questions & Quantitative Answers
As of Nov 17, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (52.6/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. SGMT trades at $9.78 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin). Growth vs. Quality Trade-Off: SGMT earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. CAMP 43.9/100 HOLD) and 2.08β · 84% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SGMT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.5); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: SGMT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), SGMT cumulative revenue shifted N/A while CAMP shifted N/A. In operating R&D and SG&A reinvestment, SGMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.
CAMP screens cheaper on headline valuation multiples. SGMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGMT (-29.5% ROE) versus CAMP (-146.1% ROE) capital efficiency.
In options market volatility and institutional positioning, SGMT carries 81.6% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.08β · 84% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CAMP vs SGMT · Reverse Pair
SGMT vs TVGN
· Sector Peer
SGMT vs ANNX
· Sector Peer
CAMP vs HLIT
· Sector Peer
CAMP vs ADTN
· Sector Peer
CAMP vs DGII
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem